A novel tripartite fusion drives treatment resistance in atypical APL; managing iTTP without TPE; hope for motherhood after allogeneic HCT
In this week's episode we’ll discuss a novel tripartite fusion drives treatment resistance in acute promyelocytic leukemia. In some patients with atypical APL, these novel retinoic acid receptor gene fusions result in truncation of the ligand binding domain of the retinoic acid receptor protein, resulting in non-responsiveness to treatment with all-trans retinoic acid. After that: managing immune thrombotic thrombocytopenia or iTTP without therapeutic plasma exchange, or TPE. Finally, hope for motherhood after allogeneic HCT.
Featured Articles:
Featured Articles:
- Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APL
- Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange
- Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)